Due Diligence Reviews & Transactional Support

due diligence review
Companies engaged in mergers, acquisitions and other corporate transactions seek our advice on conducting due diligence reviews, and on FDA-related issues that arise during these transactions. Our multidisciplinary team provides a unique, one-stop approach for our clients’ business and legal needs.

Contact

“This highly regarded firm is considered a significant force due to its broad regulatory expertise which includes advising clients on litigation, transactional and policy matters. Its deep FDA capabilities informed significant First Amendment litigation regarding off-label promotions, and its health care group has worked extensively on matters involving the impact of the Affordable Care Act.” Chambers USA

Overview

We conduct due diligence reviews for FDA-regulated companies engaging in mergers, acquisitions, licensing deals and other corporate transactions. Our experience on FDA regulatory matters allows us to identify and evaluate the significance of regulatory issues that may affect the value of a proposed transaction. Our firm’s unique depth in both life science transactions and FDA regulation enables us to incorporate regulatory diligence findings seamlessly into deal negotiations and deal terms.

Experience

Examples of our due diligence reviews and transactional support representation include providing regulatory due diligence advice and counsel to:

  • Gridiron Capital LLC in its acquisition of Performance Health & Wellness Holdings Inc. 
  • Stryker Corporation in its acquisition of Concentric Medical
  • Avista Capital Partners and its portfolio company, Navilyst Medical in the sale of Navilyst to AngioDynamics
  • Pfizer regarding the potential purchase of a pharmaceutical drug
  • TPG Capital in connection with
    • its $1.9 billion acquisition of Par Parmaceuticals
    • its sale of Fenwal to Fresenius Kabi
    • its $1.97 billion acquisition of Immucor
  • Genzyme Corporation in connection with its sale to Sanofi-Aventis for $20.1 billion in cash, plus contingent value rights